Fatty acid compounds
US-2025361217-A1 · Nov 27, 2025 · US
Methods, pharmaceutical compositions, therapeutic systems, and compounds for treating B cell malignancies
US9458123B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9458123-B2 |
| Application number | US-201314378082-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 15, 2013 |
| Priority date | Feb 15, 2012 |
| Publication date | Oct 4, 2016 |
| Grant date | Oct 4, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to a method of treating B cell malignancies, which involves administering to a subject a compound having a structure of formula (I) to cause cell death of a B cell malignancy, thereby treating the B cell malignancy in the subject. Also disclosed are a method of causing cell death of malignant B cells, pharmaceutical compositions and therapeutic systems comprising a compound having a structure of formula (I), and a compound having a structure of formula (I).
First claim
Opening claim text (preview).
What is claimed: 1. A method of causing cell death of malignant B cells of diffuse large cell lymphoma comprising: introducing a compound having a structure into a malignant B cell of diffuse large cell lymphoma under conditions effective to cause cell death of the malignant B cell. 2. The method according to claim 1 , wherein the compound is present in a pharmaceutical composition that also comprises a pharmaceutically-acceptable carrier. 3. The method according to claim 1 , wherein the malignant B cell is in vitro. 4. The method according to claim 1 , wherein the malignant B cell is in vivo. 5. The method according to claim 1 further comprising: exposing the cell to an additional therapeutic agent, wherein the additional therapeutic agent is a CHOP combination therapy.
Assignees
Inventors
Classifications
- C07D307/71Primary
attached in position 5 · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Nitrofurans (nitrofurantoin A61K31/4178) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9458123B2 cover?
- This invention relates to a method of treating B cell malignancies, which involves administering to a subject a compound having a structure of formula (I) to cause cell death of a B cell malignancy, thereby treating the B cell malignancy in the subject. Also disclosed are a method of causing cell death of malignant B cells, pharmaceutical compositions and therapeutic systems comprising a compou…
- Who is the assignee on this patent?
- Zhao Jiyong, Univ Rochester
- What technology area does this patent fall under?
- Primary CPC classification C07D307/71. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).